USCAP 2026 Annual Meeting

2026 Annual Meeting Website

2026 Annual Meeting Schedule

Print Program

Sponsors

Print

Autopsy and Forensics

Cardiac SARS-CoV-2 Viral Persistence in Decedents with Long COVID Manifesting Cardiac Symptoms: A Multi-Institutional Study from the RECOVER Program Autopsy Cohort

Mon, March 23

Hall 2

Poster Session

Part of:

Stowell-Orbison - Autopsy and Forensics

9:30 AM - 12:00 PM

Info

Poster Board Number:

279

Background:

SARS-CoV-2 RNA can persist in tissues long after initial infection, but with unclear significance. After acute illness, some patients experience persistent symptoms of potential cardiac origin, such as palpitations, chest pain, shortness of breath, and fatigue consistent with cardiac Long COVID (CLC). Cardiac viral persistence may drive CLC symptoms and could have direct implications for patient care.  We investigated whether the presence of SARS-CoV-2 reverse strand, a marker of viral replication, in the left ventricle (LV) is associated with CLC, pathologic changes and altered gene expression.

Design:

We studied 74 decedents ≥60 days from initial infection, who underwent expedited autopsy. Cardiac LV tissue was subjected to transcriptomic analysis using NanoString nCounter® HOT Panel / Coronavirus Panel Plus. Viral positivity was defined as detection of reverse strand relative to negative controls, and its associations with clinical and pathologic features were determined. Differential gene expression (DGE) analysis was performed comparing patients with (V+) and without (V-) SARS-CoV-2 reverse strand.  Immunohistochemistry (IHC) for IRF4 and in-situ hybridization (ISH) for viral spike gene positive strand were performed.

Results:

Of 74 cases, 11 were V+ and 63 were V-. There was no significant difference in demographics, comorbidities, cause of death, initial viral variant, interval from initial infection, vaccination status, and presence of myocarditis. CLC was seen in 9 (82%) of 11 V+ cases and 23 (37%) of 63 V- cases (p=0.0075). V+ cases had a shorter interval from last positive swab (median 299 vs 522 days; p=0.01) and a higher prevalence of severe acute COVID-19 (30% vs 3%; p=0.02). V+ hearts showed higher heart-weight-to-LV-wall-thickness ratios (mean 437 vs 340 g/cm; p=0.005), more frequent LV dilatation (64% vs 24%, p=0.01), and more frequent pericardial fluid ≥30 mL (40% vs 14%; p=0.048). SARS-CoV-2 ISH was positive in cardiac myocytes in V+ cases. DGE analysis showed significant alteration in the expression of 44 genes involved in inflammation and host response, particularly interferon regulatory factor 4 (IRF4). By IHC, IRF4+ cells were seen mainly in the epicardium.

Figure 1:

Click to view full size

Figure 2:

Click to view full size

Conclusion:

Detection of SARS-CoV-2 reverse strand in the hearts of a subset of patients with CLC provides molecular evidence of viral persistence that may drive the structural and immune changes underlying their symptoms, offering mechanistic insights that could inform new diagnostic and therapeutic strategies.

Disclosures:

Faye Victoria Casimero: None; Aram Krauson: None; Pritha Sen: None; David Milstone: None; Maria Martinez-Lage: None; Robert Padera: Consultant - Morair; Vergent; Vanessa Hannay: None; Zakir Siddiquee: None; Iris Lopez: None; Mayara Bearse: None; Andrea Troxel: Other - BioAge; Cellectis; Carolyn Glass: None; Thomas Flotte: None; Michelle Lamendola-Essel: None; Chloe Young: None; Phoebe Del Boccio: None; Paul Benson: None; Jonathan Melamed: None; Avi Rosenberg: None; Silvio Litovsky: None; Richard Moffitt: None; Dezhi Wang: None; Vivian Gainer: None; Ayat Abdelsalam: None; Elizabeth Handel: None; Ben White: None; Ameera Afifi: None; James Stone: None

Authors

Faye Victoria C. Casimero , MD<br>Massachusetts General Hospital, Harvard Medical School<br>Medford, MA, United States

Aram J. Krauson, PhD<br>Massachusetts General Hospital<br>Charlestown, MA, United States

Pritha Sen, MD<br>Brigham and Women's Hospital<br>Boston, MA, United States

David S. Milstone, MD, PhD<br>Brigham and Women's Hospital<br>Boston, MA, United States

Maria Martinez-Lage, MD<br>Mass General Brigham<br>Boston, MA, United States

Robert Padera, MD, PhD<br>Brigham and Women's Hospital<br>Boston, MA, United States

Vanessa Hannay, MS<br>Massachusetts General Hospital<br>Charlestown, MA, United States

Zakir Siddiquee, N/A<br>Massachusetts General Hospital<br>Cambridge, MA, United States

Iris A. Lopez, BA<br>Massachusetts General Hospital<br>Cambridge, MA, United States

Mayara Bearse, MD<br>Cedars-Sinai Medical Center<br>Beverly Hills, CA, United States

Andrea B. Troxel, ScD<br>New York University Langone Health<br>New York, NY, United States

Carolyn Glass, MD, PhD<br>Duke University Medical Center<br>Durham, NC, United States

Thomas J. Flotte, MD<br>Mayo Clinic<br>Faribault, MN, United States

Michelle F. Lamendola-Essel, DHSc<br>New York University Langone Health<br>Port Jefferson Station, NY, United States

Chloe E. Young, BS<br>New York University Langone Health<br>Ridgewood, NJ, United...